Pfizer Inc.will lower the prices on medicines for patients with drug-resistant HIV in developing countries as part of an agreement with former President Bill Clinton.Pfizer has committed to lowering price of its tuberculosis drug for patients taking second-line antiretroviral therapies for HIV/AIDS by 60% to $1 a dose.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
The medicines and prices will be available to governments that are members of the William J. Clinton Foundation's Procurement Consortium in Africa, Asia, Latin America and the Caribbean.
Mylan will make available its second-line antiretroviral treatments -- atazanavir, ritonavir, tenofovir and lamivudine. The four drugs will be available in three pills, with tenofovir and lamivudine combined into a single pill, for $475 a year. Next year the pills will be packaged together, allowing a price cut to $425.
In addition to reducing the number of pills taken per day, the products will include the first heat stable-version of ritonavir, eliminating the need for refrigeration.
It is the first time the combination has been available for less than $500 a year, according to Mr. Clinton in the press release. If fully adopted the new regimen could lead to a cumulative cost savings of $400 million over the next five years compared with recent prices for alternative treatments.
There were between 200,000 and 250,000 HIV drug-resistant patients across the developing world last year.
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
